下载此文档

COPD 素材.ppt


文档分类:办公文档 | 页数:约58页 举报非法文档有奖
1/58
下载提示
  • 1.该资料是网友上传的,本站提供全文预览,预览什么样,下载就什么样。
  • 2.下载该文档所得收入归上传者、原创者。
  • 3.下载的文档,不会出现我们的网址水印。
1/58 下载此文档
文档列表 文档介绍
New advances in COPD between 2007 and 2008 (starting from 2006)
Paul Jones MD, PhD
Professor of Respiratory Medicine
St e’s, University of London
COPD staging (FEV1/FVC < )
Stage 1
Mild
FEV1 ≥ 80% predicted
Stage 2
Moderate
FEV1 50 – 79%
Stage 3
Severe
FEV1 30 – 49%
Stage 4
Very Severe
FEV1 <30% or with respiratory failure
GOLD treatment guidelines 2007
GOLD 2006 treatment aims
Relieve symptoms
Improve exercise tolerance
Improve health status
Prevent and treat exacerbations
Prevent disease progression
Reduce mortality
Minimize side-effects
Inflammation in COPD
CD8+ T-Lymphocytes
* Adjusted for multiplicity (p = unadjusted)
Placebo (n = 68)
Seretide (n = 55)
0
40
80
120
160
200
240
280
320
Median cells/mm2
Baseline
Week 12
Baseline
Week 12
p=*
Barnes et al M 2006; 173: 736
TORCH: Study Design
SFC 500/50 bd
FP 500 bd
Salmeterol 50 bd
Placebo
Duration = 3 years
1,533
1,534
1,524
1,521
6112 patients
2 week run-in
ITT population
(any PRN or regular short-acting bronchodliator and/or theophyline)
Regions
* Australia, New Zealand, Argentina, Brazil, Chile, Mexico, South Africa & Canada
Randomised
N=6184
USA
1401 (23%)
Asia Pacific
(12%)
(China 244 patients)
Eastern Europe
1179 (19%)
Western Europe
1911 (31%)
Other*
935 (15%)

COPD 素材 来自淘豆网www.taodocs.com转载请标明出处.

相关文档 更多>>
非法内容举报中心
文档信息
  • 页数58
  • 收藏数0 收藏
  • 顶次数0
  • 上传人yuzonghong1
  • 文件大小1.63 MB
  • 时间2018-08-15
最近更新